Cell Biotech Co

Cell Biotech Co Net Change in Cash

The Net Change in Cash of Cell Biotech Co (049960.KQ) as of Nov 17, 2026 is 12.38 B KRW. In the previous year, Net Change in Cash was -3.13 B KRW — a change of -495.91% (higher).

Net Change in Cash

12.38 BKRW

YoY

-495.91%

Last updated:

Net Change in Cash of Cell Biotech Co is 2025 12.38 B KRW. Net Change in Cash of Cell Biotech Co was 2024 -3.13 B KRW. It decreases by -495.91% higher compared to the previous year.

The Cell Biotech Co Net Change in Cash history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Change in Cash
Date
Net Change in Cash
Jan 1, 2018
-274.38 M KRW
Jan 1, 2019
-3.92 B KRW
Jan 1, 2020
177.19 M KRW
Jan 1, 2021
260.35 M KRW
Jan 1, 2022
-1.40 B KRW
Jan 1, 2023
-573.48 M KRW
Jan 1, 2024
-3.13 B KRW
Jan 1, 2025
12.38 B KRW
The Cell Biotech Co Net Change in Cash history
YEARNet Change in CashYoY
12.38 BKRW-495.91%
-3.13 BKRW+445.36%
-573.48 MKRW-59.10%
-1.40 BKRW-638.53%
260.35 MKRW+46.93%
177.19 MKRW-104.52%
-3.92 BKRW+1,328.53%
-274.38 MKRW-109.08%
3.02 BKRW-9.02%
3.32 BKRW+76.02%
1.89 BKRW+201.51%
625.87 MKRW—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cell Biotech Co Stock analysis

What does Cell Biotech Co do? Cell Biotech Co., Ltd. generates revenue through the production and sale of probiotic lactobacillus products. The company manufactures lactic acid bacteria (LAB) powders, which serve as raw materials for foods and medicines targeting immunization enhancement and digestion improvement. Finished products containing LABs are sold for intestinal health improvement, carcinogen inhibition, and calcium supplementation, distributed domestically and internationally. The firm focuses on functional health applications within the probiotics market. The company's primary customers are domestic and international food and pharmaceutical manufacturers seeking functional ingredients, as well as end consumers purchasing finished probiotic products. LAB powders are supplied to food and medicine producers, while finished products reach consumers directly for health benefits. Distribution channels include both local and global markets, emphasizing the functional health segments of the industry. Cell Biotech's product portfolio centers on LAB-based solutions for health enhancement, with no additional brands or external partnerships mentioned in the business description. The company operates solely within the probiotics sector, leveraging its research and development capabilities to create products aligned with digestive and immune health needs. Cell Biotech Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Cell Biotech Co stock

Net Change in Cash of Cell Biotech Co is 12.38 B KRW in 2025.

Net Change in Cash of Cell Biotech Co changed from -3.13 B KRW to 12.38 B KRW, representing a -495.91% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Net Change in Cash Cell Biotech Co since 2006 – with annual values, charts, and detailed analysis.

Net change in cash is the total change in cash and equivalents during the period, combining operating, investing, and financing cash flows.

Net Change in Cash's KRW is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Net Change in Cash's Cell Biotech Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Cell Biotech Co

All Key Metrics — Cell Biotech Co